[Zolbetuximab联合化疗治疗her2阴性和cldn18.2阳性的局部晚期不可切除或转移性胃或胃交界腺癌]。

{"title":"[Zolbetuximab联合化疗治疗her2阴性和cldn18.2阳性的局部晚期不可切除或转移性胃或胃交界腺癌]。","authors":"Léa Jehanno, Juliette Logeart","doi":"10.1016/j.bulcan.2025.02.011","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 6","pages":"Pages 561-562"},"PeriodicalIF":0.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Zolbétuximab en association à la chimiothérapie dans les adénocarcinomes gastriques ou de la jonction œsogastrique localement avancés non résécables ou métastatiques, HER2 négatifs et CLDN 18.2 positifs\",\"authors\":\"Léa Jehanno, Juliette Logeart\",\"doi\":\"10.1016/j.bulcan.2025.02.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9365,\"journal\":{\"name\":\"Bulletin Du Cancer\",\"volume\":\"112 6\",\"pages\":\"Pages 561-562\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin Du Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0007455125001262\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin Du Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0007455125001262","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}